Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on April 30, 2025

PAIRS Foundation Unveils Free Mental Wellness App Offering Science-Backed Emotional Tools

PAIRS Foundation Unveils Free Mental Wellness App Offering Science-Backed Emotional Tools

The PAIRS Foundation has launched Yodi — a free, AI-powered app offering short, proven exercises to support mental, emotional, and physical well-being. FORT LAUDERDALE, FL, UNITED STATES, April 30, 2025 /⁨EINPresswire.com⁩/ -- After more than 50 years of …

CARLING ADRENAL CENTER BRINGS NATIONAL ATTENTION TO PHEOCHROMOCYTOMA AND OTHER ADRENAL TUMORS WITH ANY LAB TEST NOW

CARLING ADRENAL CENTER BRINGS NATIONAL ATTENTION TO PHEOCHROMOCYTOMA AND OTHER ADRENAL TUMORS WITH ANY LAB TEST NOW

TAMPA, FL, UNITED STATES, April 30, 2025 /⁨EINPresswire.com⁩/ -- The Carling Adrenal Center is shining a spotlight on Pheochromocytoma, a rare but serious adrenal tumor that can cause life-threatening spikes in blood pressure, severe headaches, sweating, …

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read Neurocrine’s announcement (link) Tokyo, Japan …

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix …

NewVue.ai and Smart Reporting Partner to Embed Adaptive Reporting in the Radiologist Cockpit

NewVue.ai and Smart Reporting Partner to Embed Adaptive Reporting in the Radiologist Cockpit

TAMPA, FL, UNITED STATES, April 30, 2025 /⁨EINPresswire.com⁩/ -- NewVue.ai, a leader in cloud-native radiology workflow orchestration, and Smart Reporting, a global innovator in AI-powered diagnostic reporting, today announced a strategic integration that …

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery …

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today …

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …

Best CBD Gummies of 2025: Cornbread Hemp CBD Products Help with Sleep, Pain, and Stress Relief

Best CBD Gummies of 2025: Cornbread Hemp CBD Products Help with Sleep, Pain, and Stress Relief

Louisville, KY, April 30, 2025 (GLOBE NEWSWIRE) -- In a market saturated with cannabidiol (CBD) products, one company continues to lead with quality, transparency, and innovation. Cornbread Hemp has officially been named the provider of the Best CBD …

CooperCompanies Appoints Barbara Carbone to Board of Directors

CooperCompanies Appoints Barbara Carbone to Board of Directors

SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. …

Teladoc Health Reports First Quarter 2025 Results

Teladoc Health Reports First Quarter 2025 Results

PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). Unless otherwise noted, percentage and …

Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided strategic, financial, and operational updates for …

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane …

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious …

Codexis to Report First Quarter 2025 Financial Results on May 14

Codexis to Report First Quarter 2025 Financial Results on May 14

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first …

Vaxart to Present at the Citizens Life Sciences Conference

Vaxart to Present at the Citizens Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that members of the management team will present at the Citizens Life Sciences conference taking place May 7-8, 2025. Presentation Details: Date and …

Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired UpLift, an innovative and tech-enabled provider of virtual mental health therapy, psychiatry and medication …

Mdxhealth to Release First Quarter 2025 Financial Results on May 14

Mdxhealth to Release First Quarter 2025 Financial Results on May 14

Company to Host Conference Call with Live Q…

Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025

Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025

Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www.inventivapharma.com   Date Nombre de titres composant le capital en circulation   Nombre total de droits de vote bruts(1)   …

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

Article R. 22-10-23 of the French Commercial Code Market: Euronext Paris ISIN code / Mnemo: FR0013233012 / IVA Web site: www.inventivapharma.com Date Number of shares outstanding Total voting rights, gross (1) Total voting rights, net (2) April 11, 2025 95 …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service